Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Bloodletting in store for UDG Healthcare and NMC, reckons Jefferies

Fri 11 January 2019 11:39 | A A A

No recommendation

No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.

(Sharecast News) - NMC Health and UDG Healthcare were given a bruising by Jefferies analysts on Friday, as they performed a check to the healthcare sector.

With its premium rating, NMC was acknowledged as their "most anti-consensus" 'underperform' rating, with a price target of cut to 2,300p as the analysts "expect the market to increasingly focus on cash conversion and potential pressures in the base business in Abu Dhabi in the basic segment".

UDG was downgraded to 'hold' from 'buy' and given a 620p target price as analysts expect market concerns around its Ashfield business to persist in 2019.

The analysts believe Mediclinic "offers value", backed by a £3.2bn freehold property portfolio.

"Momentum stories" such as Hikma Pharma were highlted and Dechra Pharma was suggested "for investors seeking non-cyclical stories".

    The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.